Medibio Announces Sponsored Research Agreement with Humanitas University 2019-06-20T10:24:58-05:00

Melbourne, Australia and Minneapolis, MN – 17 April 2019: Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF), a mental health technology company today announces a Sponsored Research Agreement with the Department of Biomedical Sciences of Humanitas University, Milan, Italy.

This research agreement will support the Company’s continued development of mental health software products based on Medibio’s intellectual property. The collaboration extends the Company’s clinical team and will reinforce clinical relevance needed to align with regulatory guidance and market needs. Medibio will maintain all intellectual property generated under this agreement.

Throughout 2019 Medibio will work closely with this highly skilled team of researchers and data scientists who have clinical backgrounds in Psychiatry and Psychology. The team’s depth of expertise is impressive, including collectively publishing 177 peer-reviewed articles focusing on subjects like panic attacks, anxiety disorders and general Psychiatry.

“Technology is the future of medicine and this partnership aligns with our focus on continuous innovation, ” said Giorgio Ferrari, the CEO of Humanitas University. “Transitioning to a modern culture of research, one which expands beyond the university in collaboration with innovative companies like Medibio, is a priority for us. This is an opportunity to improve the precision in diagnostic assessment and therapeutic choices in the field of mental health.”

Overseeing this collaboration will be Dr. Giampaolo Perna, Medibio Scientific Advisory Board member. Giampaolo Perna, M.D., Ph.D. is currently Chair of the Department of Clinical Neurosciences at San Benedetto Menni Hospital of the Hermanas Hospitalarias (Como Lake) and Academic Coordinator of Mental Health Area and Adjunct Professor at Humanitas University (Milan), in Italy. He earned his degree in Medicine and Surgery at the State University of Milan, followed by a Ph.D. and completed a residency in Psychiatry there as well. He is the Chair of WPA section on personalised psychiatry and Coeditor in chief of the Elsevier Journal “Personalized Medicine in Psychiatry”.

“Medibio has found an effective partner to assist in developing and validating our pipeline of software products,“ said Lindsey Hagan, Medibio Vice President, Strategy and Business Development. “The ultimate goal of this collaboration is to release clinical products that are meaningful to both physicians and patients while improving outcomes in mental health care delivery.”

–END–

About Medibio Limited
Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company was founded in Australia, with offices now located in Melbourne (Vic) and Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

Medibio Media Inquiries:
Kristi Hamilton
Director, Strategic Communications
kristi.hamilton@medibio.com.au
T: +1 952 232 0934

Investor Enquiries:
Peter Taylor
NWR Communications
peter@nwrcommunications.com.au
T: +61 (0) 412 036 231